-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 1, AstraZeneca voluntarily applied to lower the online price of "Sodium Zirconium Cyclosilicate Powder" from the previous 486 yuan to 340.
On January 6, 2020, AstraZeneca Sodium Zirconium Cyclosilicate Powder (Ribizol®) was approved for import in China for the treatment of adult hyperkalemia
In 2020, sodium zirconium cyclosilicate powder also participated in the medical insurance negotiations and appeared in the list of approved formalities announced by the Medical Insurance Bureau, but it did not enter the medical insurance catalog in the end.
According to the analysis of the winning bid of the Insight database, the new drug has maintained a price of 486 yuan since its launch.
Every year before medical insurance negotiations, many new drugs will actively lower their online prices.
The adjustment of the medical insurance catalogue has been initiated this year.
Note: The original text has been deleted